Related Experiment Video

Updated: Aug 12, 2026

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

Release of the serum immunosuppressive factor by monocytes in patients with Crohn's disease

M Watanabe1, T Hibi, Y Iwao

  • 1Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.

Journal of Clinical & Laboratory Immunology
|August 1, 1989
PubMed

Insights

Sera from Crohn's disease patients suppressed mouse spleen cell proliferation. Monocytes may release this immunosuppressive factor, potentially contributing to abnormal immune responses in the gut.

Area of Science:

  • Immunology
  • Gastroenterology

Background:

  • Crohn's disease is an inflammatory bowel disease characterized by an abnormal immune response.
  • The immunosuppressive effects of Crohn's disease sera and peripheral blood mononuclear cells (PBMCs) are not fully understood.

Purpose of the Study:

  • To investigate the in vitro immunosuppressive effect of sera and PBMCs from Crohn's disease patients.
  • To identify the cellular source of immunosuppressive factors in Crohn's disease.

Main Methods:

  • Sera and culture supernatants of PBMCs (adherent and non-adherent fractions) from Crohn's disease patients and controls were analyzed for immunosuppressive activity.
  • Mouse spleen cell proliferation assays were used to assess immunosuppressive effects.
  • Fractionization of culture supernatants was performed to characterize the immunosuppressive factor.

Main Results:

  • Sera from Crohn's disease patients significantly suppressed mouse spleen cell proliferation compared to controls.
  • Culture supernatants from adherent PBMCs of Crohn's disease patients exhibited potent immunosuppressive activity (96 +/- 1%).
  • Fractionization revealed that the immunosuppressive factor shares biochemical properties with previously identified serum immunosuppressive fractions.

Conclusions:

  • Monocytes in Crohn's disease patients may release a serum immunosuppressive factor.
  • This factor could contribute to impaired immune reactivity at mucosal lesions and sustained abnormal immune responses in the intestinal wall.

More Related Videos

Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro07:51

Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro

Published on: March 18, 2019

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...